Skip to main content

Advertisement

Table 1 Summary of cohort, tumour, treatment and reference standard characteristics of studies included in the individual patient data analysis

From: Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis

   Study level estimates
Variable Patients (%) Median IQR Range
Cohort characteristics     
N patients with MRI (8 studies) 300 (NA) 36 28 – 50 13 – 59
Recruitment mid-point (year) (4 studies) 144 (NA) 2003 2001 – 2005 2001 – 2006
Age, mean or median (years) (8 studies) 300 (NA) 47 46 – 48 43 – 49
Menopausal status (%)a (2 studies)
  Pre 51 (72.9) 64.6 60.4 – 68.8 60.4 – 68.8
  Peri/post 19 (27.1) 25.0 18.8 – 31.2 18.8 – 31.2
Tumour characteristics     
Clinical size, mean or median (cm)a (4 studies) 136 (NA) 4.6 4.2 – 6.6 4.0 – 8.2
T stage (%)a (4 studies)
  T1 5 (2.9) 2.9 1.0 – 5.0 0.0 – 6.2
  T2 62 (35.8) 43.0 23.9 – 50.3 6.2 – 56.2
  T3 78 (45.1) 43.6 38.3 – 49.1 37.5 – 50.0
  T4 28 (16.2) 9.8 0.0 – 30.6 0.0 – 41.7
Stage (%)a (6 studies)
  I 1 (0.5) 0.0 0.0 – 0.0 0.0 – 3.1
  II 131 (59.0) 66.1 45.0 – 78.0 27.1 – 86.7
  III 83 (37.4) 32.3 22.0 – 37.5 0.0 – 72.9
  IV 7 (3.2) 0.0 0.0 – 0.0 0.0 – 17.5
Histology (%)a (6 studies)
  IDC 191 (84.1) 86.2 74.2 – 87.8 68.8 – 90.0
  ILC or IDC/ILC 19 (8.4) 9.8 5.1 – 10.0 4.9 – 18.8
  Other 17 (7.5) 7.9 4.0 – 12.5 0.0 – 16.1
Nodal status (%)a (4 studies)
  Positive 109 (72.2) 71.0 62.5 – 80.6 56.2 – 87.8
  Negative 42 (27.8) 29.0 19.4 – 37.5 12.2 – 43.8
ER (%)a (5 studies)
  Positive 113 (60.1) 62.5 60.0 – 64.4 45.0 – 69.2
  Negative 73 (38.8) 37.5 32.2 – 40.0 15.4 – 55.0
  Unknown or NR 2 (1.1) 0.0 0.0 – 0.0 0.0 – 3.4
PR (%)a (4 studies)
  Positive 71 (44.9) 41.2 32.9 – 49.8 30.8 – 52.1
  Negative 84 (53.2) 51.5 47.5 – 59.4 48.5 – 65.0
  Unknown or NR 3 (1.9) 1.0 0.0 – 2.7 0.0 – 3.4
HER2 (%) (3 studies)
  Positive 42 (28.8) 29.2 22.5 – 33.9 22.5 – 33.9
  Negative 97 (66.4) 62.5 61.0 – 77.5 61.0 – 77.5
  Unknown or NR 7 (4.8) 5.1 0.0 – 8.3 0.0 – 8.3
Treatment     
NAC regimen (%)a (8 studies)
  Anthracycline-based 115 (38.1) 9.3 0.0 – 77.6 0.0 – 100.0
  Antracycline-taxane-based 181 (59.9) 88.1 17.4 – 100.0 0.0 – 100.0
  Other 6 (2.0) 0.0 0.0 – 2.5 0.0 – 100.0
Trastuzumab (%)a (3 studies)
  Trastuzumab used 29 (19.6) 7.3 2.1 – 42.4 2.1 – 42.4
  Trastuzumab not used 119 (80.4) 92.7 57.6 – 97.9 57.6 – 97.9
Type of surgery (%)a (8 studies)
  BCS 132 (43.1) 50.3 37.6 – 55.9 6.2 – 59.4
  Mastectomy 172 (56.2) 57.2 44.1 – 63.8 34.4 – 93.8
  No surgery 2b (0.7) 0.0 0.0 – 0.0 0.0 – 6.2
Reference standard     
Type of reference standard (%) (8 studies)
  Pathology 298 (99.3) 100.0 100.0 – 100.0 93.8 – 100.0
  Other 2b (0.7) 0.0 0.0 – 0.0 0.0 – 6.2
Time from MRI to surgery, mean or median/estimate (days) (6 studies) 228 (NA) 16 12 – 25 7 - 28
Prevalence of pCR (%) (8 studies) 300 (NA) 19.0 15.5 – 23.4 7.1 – 27.5
  1. BCS breast conserving surgery, DCIS ductal carcinoma in situ, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, IQR inter-quartile range, MRI magnetic resonance imaging, NA not applicable, NAC neoadjuvant chemotherapy, NR not reported, pCR pathologic complete response, PR progesterone receptor
  2. aCalculation of values based on total number of patients enrolled, a minority of whom may not have contributed data to this analysis
  3. bLocalisation biopsy showed the absence of residual tumour (i.e. pathologic measurement of 0.0 cm)